Log in

NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

$60.49
-0.80 (-1.31 %)
(As of 02/23/2020 02:10 PM ET)
Today's Range
$60.26
Now: $60.49
$61.42
50-Day Range
$58.32
MA: $60.53
$63.40
52-Week Range
$53.34
Now: $60.49
$86.58
Volume491,330 shs
Average Volume689,017 shs
Market Capitalization$8.51 billion
P/E Ratio20.16
Dividend YieldN/A
Beta2.02
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$599.67 million
Cash Flow$3.16 per share
Book Value$8.63 per share

Profitability

Net Income$273.74 million

Miscellaneous

Employees737
Market Cap$8.51 billion
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Wednesday, November, 6th. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.49. The company earned $168 million during the quarter, compared to analyst estimates of $152.47 million. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The firm's revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.03) earnings per share. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

How can I listen to Ionis Pharmaceuticals' earnings call?

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for IONS?

12 analysts have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $48.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $75.82 in the next year. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News headlines about IONS stock have trended very negative this week, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Ionis Pharmaceuticals.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 31st total of 7,700,000 shares. Based on an average trading volume of 983,700 shares, the short-interest ratio is presently 8.6 days. Approximately 6.6% of the shares of the stock are short sold. View Ionis Pharmaceuticals' Current Options Chain.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), BlackRock (BLK), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), Geode Capital Management LLC (1.03%) and First Trust Advisors LP (0.71%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE and Rafferty Asset Management LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., Sumitomo Mitsui Trust Holdings Inc. and Amia Capital LLP. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $60.49.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $8.51 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  605 (Vote Outperform)
Underperform Votes:  705 (Vote Underperform)
Total Votes:  1,310
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel